Published Research

Establishing a model spinal cord injury in the African green monkey for the preclinical evaluation of biodegradable polymer scaffolds seeded with human neural stem cells. Download PDF

The use of biomaterials for transplantation and directed differentiation of nerve progenitor cells for central nervous system repair. Download PDF

InVivo scientists engineer a drug delivery and tissue engineering method to increase survival of neural stem cells after transplantation into the injured spinal cord. Download PDF

Design and Fabrication of biocompatible polymer implants suitable for neural tissue engineering, drug delivery and prosthetics. Download PDF

Functional recovery following spinal cord injury mediated by novel polymer scaffolds that can be used alone and/or as carriers to administer human neural stem cells. Download PDF

Development Portfolio

InVivo Therapeutics is focused on utilizing polymers as a platform technology to develop and commercialize groundbreaking treatments for spinal cord injuries (SCI). InVivo’s technologies encompasses multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).

Background

InVivo’s proprietary technology was co-invented by Robert S. Langer, ScD, the David H. Koch Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, affiliated with Massachusetts General Hospital. The patent rights that are the basis for InVivo’s products are under an exclusive, worldwide license from Children’s Medical Center Corporation and Massachusetts Institute of Technology.

Data on InVivo’s technology was first published in PNAS in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models including rodent and non-human primate models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010.